About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success

By: Newsfile

Thailand's National Innovation-Mangosteen-Based Immunotherapy Fights HIV/AIDS

Bangkok, Thailand--(Newsfile Corp. - June 18, 2025) - The Operation BIM research team from Asian Phytoceuticals Public Company Limited, led by Professor Dr. Pichaet Wiriyachitra, has announced a significant achievement in immunotherapy innovation using Fortified Mangosteen Extracts. This natural formulation has helped 80 individuals living with HIV/AIDS reach a state known as "ByeByeHIV", characterized by strong health and, in some cases, the complete eradication of the virus from their bodies. The study has been published in the international journal Clinical Immunology Research under the title "ByeByeHIV with Thai Innovation."

Cannot view this image? Visit: https://images.newsfilecorp.com/files/8814/255952_45babc9eb467392b_002.jpg

Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8814/255952_45babc9eb467392b_002full.jpg

According to the Ministry of Public Health, in 2025, Thailand is projected to have 8,862 new HIV cases, 10,217 people have died from AIDS-related conditions, while 568,565 individuals are living with HIV.

"ByeByeHIV" refers to a condition where HIV/AIDS patients can reduce their viral load to undetectable levels without the use of antiretroviral drugs (ARVs) while maintaining good health. It also applies to those who had adverse side effects from ARVs and can now discontinue treatment while staying healthy and HIV-undetectable.

The ByeByeHIV innovation is based on a natural extract formula composed of mangosteen, black sesame, soy, guava, and Centella asiatica. This dietary supplement, approved by the Thai FDA, boosts immune functions—especially Th1, Th17, and Killer T cells—targeting infected cells and repairing HIV- and ARV-induced telomere damage.

Based on the February 2024 publication titled "ByeByeHIV with Thai Innovation", (ByeByeHIV with Thai Innovation: https://www.scivisionpub.com/abstract-display.php?id=3167) the formula successfully helped two groups:

  • Group A: 24 HIV-positive individuals never on ARVs

  • Group B: 26 individuals previously treated with ARVs

By December 2024, both groups expanded to 40 participants each, all of whom achieved ByeByeHIV.

The latest journal article, ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A), reports all 40 participants in Group A achieved ByeByeHIV. Notably, 15 individuals stopped the mangosteen-based regimen for 6 months to over 4 years while maintaining undetectable viral loads and excellent health. The first participant to discontinue the formula has now been virus-free for nearly 10 years. This suggests complete HIV eradication for the 15 individuals.

The Group B study (Progress Update on 40 Cases with Prior Use of ARV Drugs) shows that all 40 participants also reached ByeByeHIV, with 15 discontinuing the regimen for 3 months to over 2 years—remaining healthy and HIV-free. This implies HIV/AIDS may now be curable without relapse.

ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of

ARV Drugs (Group A) https://www.scivisionpub.com/abstract-display.php?id=3769

ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases with Prior Use of

ARV Drugs (Group B) https://www.scivisionpub.com/abstract-display.php?id=3770

These three remarkable recoveries highlight the potential of natural extract-based innovations in HIV treatment—restoring life quality to normalcy. All three individuals have publicly come forward and now serve as mentors, inspiring others to overcome stigma and reclaim their lives.

Professor Dr. Pichaet summarized, "This study confirms the potential of ByeByeHIV formula as a viable alternative for HIV patients unable to tolerate ARVs or new patients avoiding long-term ARV use. This marks a historic milestone for Thailand—challenging the 40-year belief that HIV/AIDS cannot be cured."

"This Thai national innovation deserves global recognition for safely awakening the body natural healing power without side effects. Though categorized as a supplement, it has achieved what pharmaceuticals could not. Legal frameworks should evolve to reflect modern scientific breakthroughs."

Contact Info:
Name: APCO Bangkok Office
Email: apco@apco.co.th
Organization: Asian Phytoceuticals Public Company Limited
Address: 30th Floor, AIA Capital Center, 89 Ratchadaphisek Road, Dindaeng District, Bangkok 10400, Thailand
Phone: 0-2646-4800
Website: https://www.apco.co.th

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255952

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.